Valuation: Moderna, Inc.

Market Cap 78.9B 71.86B 66.22B 60.23B 113B 7,306B 119B 806B 320B 3,991B 296B 290B 12,524B P/E 2026 *
-26.7x
P/E 2027 * -43.9x
Enterprise Value 74.04B 67.44B 62.14B 56.53B 106B 6,857B 111B 756B 301B 3,745B 278B 272B 11,753B EV / Sales 2026 *
30.7x
EV / Sales 2027 * 27.9x
Free-Float
92.83%
Yield 2026 *
-
Yield 2027 * -
1 day-2.17%
1 week-12.70%
Current month-12.05%
1 month-20.67%
3 months+34.36%
6 months+312.61%
Current year+561.24%
1 week 189.98
Extreme 189.98
222.42
1 month 179.53
Extreme 179.53
280.8
Current year 29.81
Extreme 29.81
280.8
1 year 23.54
Extreme 23.545
280.8
3 years 22.28
Extreme 22.28
280.8
5 years 22.28
Extreme 22.28
376.65
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap. Importance
15/10/26 Exercice

Chairperson

192,049 0.0481%
5/10/26 Other

Chief Operating Officer

125,000 0.0313%
5/10/26 Exercice

Chief Financial Officer

3,612 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-2.17%-12.70%+722.09%+152.79% 78.9B
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average +0.08%-5.55%+94.72%+83.36% 415B
Weighted average by Cap. +0.25%-5.33%+39.27%+89.11%

Financials

2026 *2027 *
Net sales 2.41B 2.2B 2.03B 1.84B 3.46B 224B 3.63B 24.66B 9.8B 122B 9.06B 8.87B 383B 2.69B 2.45B 2.26B 2.05B 3.85B 249B 4.05B 27.45B 10.91B 136B 10.08B 9.87B 427B
Net income -2.9B -2.65B -2.44B -2.22B -4.16B -269B -4.37B -29.67B -11.79B -147B -10.9B -10.67B -461B -1.68B -1.53B -1.41B -1.28B -2.4B -155B -2.53B -17.15B -6.81B -84.9B -6.3B -6.17B -266B
Net Debt -4.86B -4.42B -4.08B -3.71B -6.96B -450B -7.31B -49.61B -19.72B -246B -18.22B -17.84B -771B -3.93B -3.58B -3.3B -3B -5.63B -364B -5.91B -40.14B -15.95B -199B -14.74B -14.43B -624B
Projected Income Statement - Annual - Moderna, Inc.
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (93.1%); - revenue from grants (1.2%). - revenue from collaboration agreements (0.7%); - revenue from royalties and licensing (1.3%); At the end of 2025, the group's portfolio comprises 37 products in clinical development. Net sales are distributed geographically as follows: the United States (64.1%), Europe (2.8%) and other (33.1%).
Employees
4,700
Date Price Change Volume
20/11/26 US$195.00 -2.17% 9,687,633
19/11/26 US$199.33 +1.29% 8,204,149
18/11/26 US$196.79 -4.84% 6,986,325
17/11/26 US$206.80 -3.93% 8,277,036
16/11/26 US$215.27 -3.63% 7,023,751
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Moderna, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
195.00USD
Average target price
164.53USD
Spread / Average Target
-15.63%
  1. Stock Market
  2. Stocks
  3. MRNA Stock